The Corbett Report

Philip K. Dick’s The Three Stigmata of Palmer Eldritch – Film, Literature and the New World Order

Interview 1804 – James Corbett Explains Musk, AI and Solutions to Dr. Mercola

via Dr. Mercola’s Censored Library: In this interview—RECORDED ON MAY 8TH, 2023, BEFORE ELON MUSK APPOINTED WEF INSIDER LINDA YACCARINO AS NEW TWITTER CEO—Dr. Joseph Mercola interviews James Corbett about Elon Musk’s military and governmental ties, the controlled opposition infighting psyop, and the solutions we can implement to avoid the technocratic AI transhuman nightmare of the globalists.

10 Climate Myths Debunked (in 60 seconds!)

Dec 10, 2013 | Videos

1984: Warning or Conditioning? (video)

Dec 9, 2013 | Videos

Mandela’s Legacy, Eurozone Woes – Geneva Business Insider

Dec 9, 2013 | Videos

Interview 787 – The Geneva Business Insider with David Smith

Dec 9, 2013 | Interviews

David L. Smith of the Geneva Business Insider blog joins us once again for our monthly conversation on economics, finance and politics. This month we tackle the life and legacy of Nelson Mandela, the latest in the Eupocalypse with the latest abysmal stats out of France, and a new Swiss initiative to provide every Swiss citizen a guaranteed basic income.

1984: Warning or Conditioning? – Questions For Corbett #012

Dec 7, 2013 | Questions For Corbett

On this edition of Questions For Corbett, James rolls up his sleeve and answers your burning questions, from Arafat’s polonium poisoning to land ownership to KAL 007, JP Morgan, predictive programming and everyone’s burning question: who is the British woman who introduces the podcast?

Interview 786 – Bruce Levine Dissects the DSM-5

Dec 6, 2013 | Interviews

Author and practicing clinical psychologist Dr. Bruce Levine of BruceLevine.net joins us today to discuss the DSM-5, the latest edition of the Diagnostic and Statistical Manual (DSM) published by the American Psychiatric Association. We address concerns about the DSM’s scientific credibility and detail the DSM task force’s conflicts of interest in their to the pharmaceutical industry.